This study looks at how using a special dye called gadolinium-based contrast agents (GBCAs) affects body movement and mental skills in adults. Researchers want to see if having these agents multiple times over five years changes how people move and think. The study will include about 2,076 adults who need regular MRI or other imaging tests for health reasons. Everyone in the study will have yearly MRI or imaging tests and will visit the study doctor several times for tests and check-ups.
The trial's ID number is NCT04373564. This is a Phase 4 study, meaning it looks at how well the treatment works in real-world settings. It is regulated by the FDA and aims to include about 2,076 participants.
Who can join
Adults aged 18 to 64 can join this study. They must be neurologically normal, meaning they should not have any major brain or mental health issues. Those who have never had a gadolinium injection can join the control group. Participants must agree to have an MRI of the brain at the start and after five years. The team will confirm who meets the eligibility criteria before joining.
Conditions
Motor Function, Cognitive Function, Contrast Media
Age group
Adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants are placed in different groups based on their past experiences with gadolinium. Some will receive linear GBCAs during their MRIs, while others will receive macrocyclic GBCAs. A third group will not receive any GBCAs at all. Everyone will undergo a series of physical and mental tests, as well as blood and urine samples to check gadolinium levels.
Where
This trial is enrolling at 16 locations. Recruiting sites are listed first.